| 1.37 -0.05 (-3.52%) | 10-30 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |   |
|||
| Targets | 6-month : | 1.75 | 1-year : | 2 |
| Resists | First : | 1.5 | Second : | 1.72 |
| Pivot price | 1.33  |
|||
| Supports | First : | 1.15 | Second : | 0.96 |
| MAs | MA(5) : | 1.36 |
MA(20) : | 1.35 |
| MA(100) : | 2.18 |
MA(250) : | 1.89 |
|
| MACD | MACD : | -0.2 |
Signal : | -0.2 |
| %K %D | K(14,3) : | 69.5 |
D(3) : | 63.4 |
| RSI | RSI(14): 43.7 |
|||
| 52-week | High : | 3.53 | Low : | 0.75 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.[ EQ ] has closed below upper band by 38.9%. Bollinger Bands are 45.7% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 7 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 1.41 - 1.42 | 1.42 - 1.43 |
| Low: | 1.28 - 1.29 | 1.29 - 1.3 |
| Close: | 1.36 - 1.37 | 1.37 - 1.38 |
Equillium, Inc. is a clinical-stage biopharmaceutical company focused on developing and bringing to market products designed to address severe autoimmune and inflammatory (immuno-inflammatory) disorders where current treatment options are insufficient. The company's primary drug candidate is itolizumab (EQ001), a monoclonal antibody in clinical development that targets the novel CD6 immune checkpoint receptor. Itolizumab is currently in Phase III trials for acute graft-versus-host disease, has completed Phase Ib studies for asthma, and is also undergoing Phase Ib trials for lupus nephritis. In addition to itolizumab, Equillium is advancing EQ101 for the treatment of cutaneous T cell lymphoma and alopecia areata, and EQ102, which targets various gastrointestinal conditions. Headquartered in La Jolla, California, the company was incorporated in 2017 and previously operated as Attenuate Biopharmaceuticals, Inc. before changing its name to Equillium, Inc. in May 2017.
Mon, 26 Oct 2026
Another $20 million is expected to fund planned operations into 2029 after a gut-targeted drug's first dose. - Stock Titan
Wed, 12 Aug 2026
Equillium Inc (NASDAQ: EQ) Share Price, EQ Stock News, EQ Share Price & Updates - kalkine.ca
Wed, 22 Jul 2026
Equillium: The Market Seems To Have Already Priced In Phase 1 Success (NASDAQ:EQ) - Seeking Alpha
Thu, 25 Jun 2026
EQ Forecast — Price Target — Prediction for 2027 - TradingView
Thu, 18 Jun 2026
23% Of This Equillium Insider's Holdings Were Sold - Simply Wall Street
Wed, 10 Jun 2026
Analysts Grow More Confident In Equillium’s (EQ) Lead Asset EQ504 - Yahoo Finance
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Outperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 63 (M) |
| Shares Float | 37 (M) |
| Held by Insiders | 16 (%) |
| Held by Institutions | 65.7 (%) |
| Shares Short | 5,540 (K) |
| Shares Short P.Month | 5,370 (K) |
| EPS | -0.15 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0.87 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -34 % |
| Return on Equity (ttm) | -59 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -0.31 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -20 (M) |
| Levered Free Cash Flow | -14 (M) |
| PE Ratio | -9.79 |
| PEG Ratio | 0 |
| Price to Book value | 1.55 |
| Price to Sales | 0 |
| Price to Cash Flow | -4.36 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|